Journal
JOURNAL OF CONTROLLED RELEASE
Volume 190, Issue -, Pages 465-476Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2014.06.042
Keywords
Polymeric micelles; Clinical trials; Anticancer drugs; Gene delivery; Ligand-mediated targeting
Funding
- Japan Society for the Promotion of Science (JSPS)
- Center of Innovation (COI), the Program from Japan Science and Technology Agency (JST)
- Takeda Science Foundation
- [25750172]
- Grants-in-Aid for Scientific Research [25750172] Funding Source: KAKEN
Ask authors/readers for more resources
Targeting tumors with long-circulating nano-scaled carriers is a promising strategy for systemic cancer treatment. Compared with free small therapeutic agents, nanocarriers can selectively accumulate in solid tumors through the enhanced permeability and retention (EPR) effect, which is characterized by leaky blood vessels and impaired lymphatic drainage in tumor tissues, and achieve superior therapeutic efficacy, while reducing side effects. In this way, drug-loaded polymeric micelles, i.e. self-assemblies of amphiphilic block copolymers consisting of a hydrophobic core as a drug reservoir and a poly(ethylene glycol) (PEG) hydrophilic shell, have demonstrated outstanding features as tumor-targeted nanocarriers with high translational potential, and several micelle formulations are currently under clinical evaluation. This review summarizes recent efforts in the development of these polymeric micelles and their performance in human studies, as well as our recent progress in polymeric micelles for the delivery of nucleic acids and imaging. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available